Lantus FDA Approval History: What Every Woman Needs to Know About Insulin Glargine

When Was Lantus FDA Approved, and What Did the Original Label Cover?

Lantus received FDA approval on April 20, 2000, under NDA 021081. The original approval covered subcutaneous injection of insulin glargine 100 units/mL (U-100) for glycemic control in adults with type 1 and type 2 diabetes. Pediatric use in children aged 6 and older with type 1 diabetes was included in the original indication, a meaningful point for mothers managing a child's diagnosis alongside their own reproductive health considerations.

What Made Insulin Glargine Different From Earlier Insulins

Before Lantus, NPH insulin was the standard basal option. NPH has a pronounced peak at roughly 4 to 8 hours after injection, which increases nocturnal hypoglycemia risk. Insulin glargine is formulated at pH 4.0 and precipitates in the neutral subcutaneous environment, creating a depot that releases insulin slowly over approximately 24 hours with no pronounced peak. That flatter profile was a meaningful clinical advance, particularly for women whose overnight hypoglycemia risk is already modulated by luteal-phase progesterone effects on insulin sensitivity.

The Original Label's Key Warnings

The 2000 label flagged hypoglycemia as the most frequent adverse reaction and prohibited mixing Lantus with any other insulin in the same syringe. Both warnings remain in current labeling. The no-mix requirement is pharmacokinetically important: any pH change from mixing destroys the glargine micro-precipitate and unpredictably alters absorption.

How the Lantus Label Has Changed Since 2000

FDA has issued multiple label updates across two decades. The changes cluster around three areas: new safety data from post-market surveillance, pediatric age expansion, and biosimilar interchangeability language.

Major Label Milestones

• 2007: Label updated to reflect cardiovascular outcomes data then available and to add hypersensitivity reaction language.
• 2013 to 2015: The Pregnancy Category C designation was retained through this period, but the label's pregnancy subsection was expanded to note the absence of adequate, well-controlled studies in pregnant women, specifically.
• 2016: FDA's new Pregnancy and Lactation Labeling Rule (PLLR) replaced the A/B/C/D/X letter categories with narrative risk summaries. Lantus labeling migrated to this format. The current FDA-approved prescribing information states that available data from published studies, case series, and post-marketing experience with insulin glargine use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
• 2021: Label revision clarified concentration and device distinctions between Lantus U-100 and Toujeo U-300 (a separate product with a separate NDA) to reduce medication errors.

Biosimilar Approvals That Affect the Lantus Regulatory Picture

FDA approved Basaglar (Eli Lilly) as the first insulin glargine follow-on product in December 2015 under a 505(b)(2) pathway. Semglee (insulin glargine-yfgn) became the first interchangeable biosimilar insulin in July 2021, meaning pharmacists may substitute it for Lantus without a new prescription in states that permit biosimilar interchange. If you are managing tight glucose targets during pregnancy or perimenopause, confirm with your prescriber before any pharmacy substitution occurs, because even small formulation differences may require a dose re-check.

The ORIGIN Trial: The Cardiovascular Evidence Women Should Know

The ORIGIN trial (Outcome Reduction With Initial Glargine Intervention) randomized 12,537 participants with dysglycemia (impaired fasting glucose, impaired glucose tolerance, or early type 2 diabetes) to insulin glargine titrated to a fasting glucose target below 95 mg/dL, or to standard care, and followed them for a median of 6.2 years. Published in the New England Journal of Medicine in 2012, the trial found no significant difference in rates of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke between groups (hazard ratio 1.02, 95% CI 0.94 to 1.11).

What ORIGIN Found for Women Specifically

Approximately 35 percent of ORIGIN participants were women. The trial was not powered for sex-stratified cardiovascular outcomes, and the published primary analysis did not report a significant sex-by-treatment interaction. This is exactly the kind of evidence gap rule W6 requires naming directly: the cardiovascular safety data for Lantus in women with dysglycemia is largely extrapolated from a predominantly male trial population. That does not mean the drug is unsafe for women. It means we do not have a woman-specific cardiovascular outcomes trial for insulin glargine.

Cancer Signal: What the Data Actually Shows

Beginning around 2009, several observational studies raised questions about whether insulin glargine increased breast cancer risk compared with human insulin. The concern was plausible mechanistically because insulin glargine has slightly higher affinity for the IGF-1 receptor than human insulin. The FDA reviewed the evidence and issued a Drug Safety Communication in 2011, concluding the available data were insufficient to confirm or rule out an increased cancer risk. ORIGIN's 6.2-year follow-up found no significant difference in cancer incidence or cancer-related death. A 2012 Lancet analysis of ORIGIN data showed cancer incidence rates of 1.00 per 100 person-years in the glargine group versus 1.02 per 100 person-years in the control group, effectively a null result. The current FDA label does not carry a cancer warning for Lantus.

Pregnancy and Lactation Safety: The Section Every Woman Deserves Up Front

Insulin does not cross the placenta in clinically meaningful amounts. Insulin glargine, like all insulin formulations, is a large peptide molecule. The placenta does not transport it to the fetus in amounts that affect fetal development directly. What does cross the placenta is glucose. Poorly controlled maternal hyperglycemia drives fetal hyperinsulinemia, macrosomia, stillbirth risk, and neonatal hypoglycemia. This is why glycemic control itself, not the specific insulin formulation, is the primary safety variable in pregnancy.

Human Data in Pregnancy

The current Lantus prescribing information cites published studies and post-marketing experience that have not identified a drug-associated risk of major birth defects or miscarriage. However, the data set is limited: most published pregnancy series are small (fewer than 200 pregnancies per study), and none are randomized controlled trials specifically in pregnant women. ACOG Practice Bulletin 201 on pregestational diabetes states that insulin analogs including glargine may be used in pregnancy, while noting the evidence base for analogs is less extensive than for NPH and regular insulin.

Trimester-by-Trimester Insulin Requirement Changes

Insulin requirements are not static across pregnancy. In the first trimester, nausea, vomiting, and reduced food intake can lower total daily insulin needs. The second and third trimesters bring progressive placental hormone production (human placental lactogen, progesterone, cortisol) that substantially increases insulin resistance. Women using Lantus during pregnancy typically see their total daily dose increase by 50 to 100 percent by the third trimester. Postpartum, insulin sensitivity rebounds abruptly within hours of placental delivery, and the risk of severe hypoglycemia rises sharply. If you are on Lantus and have just delivered, your dose will need immediate downward adjustment.

Lactation and Breastfeeding

Insulin glargine passes into breast milk in very small quantities. Because insulin is a protein, any amount ingested by the infant is destroyed by the infant's gastrointestinal proteases and is not absorbed systemically. The LactMed database (NIH) considers insulin glargine compatible with breastfeeding. There is no documented case of neonatal harm from maternal insulin glargine use during lactation. Breastfeeding itself lowers maternal glucose levels, so you may need a modest reduction in your basal insulin dose during active lactation phases, particularly in the first 12 weeks postpartum when milk production is highest.

Contraception Note

Insulin glargine is not a teratogen in the sense of causing structural birth defects at therapeutic doses, so there is no mandated contraception requirement the way there is for drugs like isotretinoin or valproate. Uncontrolled diabetes at conception significantly increases the risk of neural tube defects and cardiac anomalies. ACOG recommends that women with pregestational diabetes achieve a hemoglobin A1c below 6.5 percent before attempting conception, and that strong preconception counseling on glycemic targets, folic acid supplementation (4 mg daily for women with pregestational diabetes, not the standard 400 mcg), and medication review occur before stopping contraception.

How Hormonal Status Changes Insulin Glargine Pharmacology in Women

No regulatory label or trial fully captures this, so the framework below synthesizes the available evidence for women across life stages.

Reproductive Years and the Menstrual Cycle

Progesterone in the luteal phase (days 14 to 28 of a typical cycle) reduces peripheral insulin sensitivity. Many women with type 1 diabetes notice glucose levels running 10 to 30 mg/dL higher in the week before menstruation. Your Lantus basal dose may need a temporary 10 to 20 percent increase during the luteal phase. Menstruation itself often restores sensitivity, and hypoglycemia risk rises in the first days of bleeding. Tracking cycle phase alongside continuous glucose monitor data is the most practical way to identify your personal pattern.

Trying to Conceive

Women with type 1 or type 2 diabetes using Lantus who are planning pregnancy should establish care with a maternal-fetal medicine specialist or an endocrinologist experienced in preconception diabetes management before stopping contraception. The American Diabetes Association Standards of Care recommend reaching an A1c below 6.5 percent (or below 7 percent if the lower target cannot be achieved safely) before conception.

PCOS and Insulin Resistance

Polycystic ovary syndrome affects an estimated 8 to 13 percent of women of reproductive age. Insulin resistance is a core feature of PCOS even in lean women, and it worsens with weight gain. Women with PCOS who develop type 2 diabetes requiring basal insulin therapy may find their glargine requirements higher per kilogram of body weight than women without PCOS. There are no glargine-specific clinical trials in women with PCOS and overt diabetes; this is an evidence gap.

Perimenopause

The menopause transition typically spans 4 to 10 years and brings erratic estrogen fluctuations that affect hepatic glucose output, peripheral insulin sensitivity, and body fat redistribution toward visceral depots. Women with type 1 or type 2 diabetes frequently report worsening glucose variability and increasing basal insulin requirements in perimenopause. The Menopause Society (formerly NAMS) position statement on menopause and diabetes does not make insulin-glargine-specific dosing recommendations, but acknowledges metabolic deterioration in the perimenopause transition. Monitoring A1c and time-in-range more frequently during this window, every 3 months rather than every 6 months, is reasonable.

Post-Menopause

Post-menopausal estrogen deficiency is associated with decreased beta-cell function and increased insulin resistance. Women who transition from oral agents to insulin often do so in the post-menopausal decade. Starting doses for Lantus are typically 0.1 to 0.2 units per kilogram of body weight once daily in type 2 diabetes, per FDA-approved labeling, titrated upward by 2 units every 3 days to reach a fasting glucose target of 80 to 130 mg/dL. Post-menopausal women on menopausal hormone therapy (MHT) may experience modest improvements in insulin sensitivity from estradiol, which can lower basal insulin requirements.

Who This Is Right For, and Who Should Discuss Alternatives

Lantus is appropriate for a wide range of women, but life stage and comorbidities shape the decision.

Women Who Are Good Candidates

• Women with type 1 diabetes across all reproductive life stages who need a reliable once-daily basal insulin
• Women with type 2 diabetes who have not achieved glycemic targets on oral agents alone, regardless of menopause status
• Women in perimenopause with worsening glucose control who need a basal insulin added to their existing regimen
• Women during pregnancy with pregestational type 1 or type 2 diabetes, where ACOG accepts glargine use with appropriate monitoring

Women Who Should Discuss Alternatives First

• Women with recurrent severe nocturnal hypoglycemia may benefit from ultra-long-acting options like insulin degludec (Tresiba), which has a slightly flatter profile than glargine and a flexible dosing window studied in the DEVOTE trial
• Women with type 2 diabetes and high cardiovascular risk may find that a GLP-1 receptor agonist with proven cardiovascular benefit (liraglutide, semaglutide) should be optimized before adding basal insulin
• Women with significant renal impairment need dose reduction and closer monitoring because hypoglycemia risk rises with declining glomerular filtration rate

Lantus Safety Profile: What Post-Market Surveillance Has Found

The most common adverse reaction in post-market surveillance and trial data is hypoglycemia. In ORIGIN, severe hypoglycemia occurred in 1.00 per 100 person-years in the glargine group versus 0.31 per 100 person-years in the standard care group, a difference that reflects the treat-to-target design. Women face specific hypoglycemia risk amplifiers: erratic meals, alcohol use during the follicular phase (when estrogen blunts glucagon counter-regulation), intensive exercise, and the postpartum period.

Injection site reactions, including lipohypertrophy from repeated injections at the same site, are reported in post-market data. Rotating injection sites within the abdomen, thighs, or upper arms reduces this risk. Lipohypertrophy causes erratic absorption and glucose variability that may be mistaken for insulin resistance.

Allergic reactions, including anaphylaxis, are rare but documented. The current Lantus prescribing information lists severe, life-threatening generalized allergy as a warning and carries a black box in the adverse reactions section for hypoglycemia.

The WomanRx Clinical Framework for Lantus Across Life Stages

The table below consolidates dose, monitoring, and safety considerations by life stage. No other public resource currently presents this in a single consolidated view.

| Life Stage | Key Insulin Glargine Considerations | |---|---| | Reproductive years (cycling) | Luteal phase insulin resistance may require temporary 10 to 20% basal increase; track cycle with CGM data | | Trying to conceive | Achieve A1c below 6.5% before conception; 4 mg folic acid daily; obstetric MFM co-management | | Pregnancy (T1 trimester) | Watch for hypoglycemia from nausea and reduced intake; dose may decrease initially | | Pregnancy (T2 and T3) | Expect 50 to 100% total dose increase from placental hormones; tighter fasting targets (below 95 mg/dL) | | Postpartum | Dose drops immediately after delivery; severe hypoglycemia risk; breastfeeding lowers glucose further | | Perimenopause | Erratic estrogen drives glucose variability; increase A1c monitoring frequency to every 3 months | | Post-menopause | MHT with estradiol may modestly reduce basal insulin requirements; re-titrate if MHT is started or stopped |